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Objectives: The aim of this study was to test the feasibility of conducting rigorous,
nonrandomized studies (NRSs) of healthcare interventions using existing clinical
databases in terms of the following: recruiting a large representative sample of hospitals,
identifying eligible cases, matching cases to controls to achieve similar baseline
characteristics, making meaningful comparisons of outcomes, and carrying out subgroup
analyses.
Methods: Data were extracted from the Intensive Care National Audit & Research
Centre’s Case Mix Programme Database to investigate the impact of management with a
pulmonary artery catheter (PAC) in intensive care unit (ICU) patients. Participating ICUs
were invited to collect additional data for the analysis. Patients managed with a PAC were
matched to control patients on their propensity score. Hospital mortality was then
compared between the two groups.
Results: Of 117 eligible ICUs, 68 (58 percent) agreed to participate, of which 57 (84
percent) collected additional data. Although a slightly higher proportion of larger ICUs in
university hospitals participated, the patient case-mix was similar to that in
nonparticipating ICUs. Almost all patients managed with a PAC (98 percent) were
successfully matched to patients managed without a PAC. The two groups were similar for
baseline characteristics. However, hospital mortality was worse for PAC patients than for
non-PAC patients (odds ratio, 1.28; 95 percent confidence interval, 1.06–1.55). Subgroup
analysis suggested that the impact of management with a PAC was modified by severity
of illness.
Conclusions: Rigorous NRSs are feasible if they are based on data from high-quality
clinical databases. However, the reliability of estimated treatment effects from such
studies requires further investigation.
Keywords: Nonrandomized studies, Case-mix adjustment, Propensity scores, Pulmonary
artery catheter, Clinical databases
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Clinical databases for healthcare evaluation
While randomized controlled trials (RCTs) provide the
method with the greatest internal validity for evaluating
healthcare interventions (3;5;21), most trials pay little or no
attention to their external validity, as they are often conducted
in single centers which are unrepresentative of the way most
heath care is delivered. This, combined with the difficul-
ties or impossibility of conducting RCTs of many health-
care interventions (4;16;17), underlines the importance of in-
vestigating whether rigorous nonrandomized studies (NRSs)
can provide an alternative or at least complementary method
(9;11;16;17;19).
Concern continues to be expressed about the value of
NRSs, particularly when the data used are extracted from ex-
isting databases (5). While such criticisms are well-founded
with regard to many routine administrative databases, maybe
high-quality clinical databases should not be so readily dis-
missed. Many of the latter share some of the methodological
strengths of RCTs such as standard rules and definitions for
recording data, complete and prospective data collection, and
comprehensive patient follow-up (6;10;13;16). In addition,
unlike most RCTs, such databases have high external va-
lidity as they usually include data from large numbers of
centers.
Our aim was to test the feasibility of conducting a
NRS of a healthcare intervention using data from an ex-
isting clinical database. To do this, we selected the use of
the pulmonary artery catheter (PAC) for managing critically
ill patients in UK intensive care units (ICUs). The reason
for this selection was that in 2002, when this study was
designed, there was increasing concern about the clinical
effectiveness of management with a PAC. An NRS from
the United States, published in 1996 (8), had reported that
management with a PAC was associated with a significantly
higher hospital mortality compared with management with-
out a PAC (odds ratio [OR], 1.39; 95 percent confidence in-
terval [CI], 1.15 – 1.67). Although two further NRSs also
reported higher mortality, in neither was the OR statisti-
cally significant (p < .05) (1;18). Further uncertainty arose
because all three NRSs were restricted to data collected
from between one and five U.S. teaching hospitals, thereby
challenging their external validity. Despite the widespread
concerns that these NRSs had generated about the use of
PACs in critical care, at the time, only two small RCTs
had been published (12;22), which both found statistically
nonsignificant higher mortality associated with use of the
PAC.
Against this background, our objectives were to inves-
tigate the feasibility of nesting a NRS in an existing, high-
quality clinical database in terms of being able to recruit
a large representative sample of ICUs, supplement routine
datasets with additional ad hoc variables, identify eligible
cases, adjust for differences in case-mix to enable mean-
ingful comparisons of outcomes, and to conduct subgroup
analyses.
METHODS
Design
The outcomes of a cohort of patients managed with a PAC
were compared with a matched cohort of patients man-
aged without a PAC using data from the Case Mix Program
Database (CMPD) run by the Intensive Care National Audit
& Research Centre (ICNARC) (13). At the time, the CMPD
had Section 60 (of the Health and Social Care Act) support
from the Patient Information Advisory Group, which allowed
for the use of patient identifiable data without their consent.
An information poster about the CMPD is displayed in all
participating critical care units and an information sheet ex-
plaining the purpose of the CMPD is made available for all
competent patients and for all next-of-kin.
Participants
General ICUs participating in the CMPD were invited to par-
ticipate in an additional audit of selected treatments and car-
diovascular monitoring. Between May 2003 and December
2004, participating ICUs recorded whether or not the patient
had received mechanical ventilation, renal replacement ther-
apy, or had been managed with a PAC during their stay in the
ICU. Specialist ICUs, such as neurosciences ICUs, and high
dependency units (HDUs) were excluded from the study.
For the PAC group, consecutive admissions to partici-
pating ICUs between May 2003 and December 2004 were
eligible for inclusion if they were aged 16 years and older
and the PAC had been placed after admission to the ICU.
Patients admitted electively for preoperative optimization or
who had been declared brain dead and were having a PAC
placed for hemodynamic optimization before organ donation
were excluded. For the non-PAC group, the same inclusion
criteria were applied except management with a PAC.
Data Collection and Preparation
The following data were abstracted from the CMPD: patient
identifier – sex and postcode; raw clinical data for the IC-
NARC risk prediction model (Table 1) (14), treatments (va-
soactive drugs and mechanical ventilation) received during
the first 24 hours in the ICU; mechanical ventilation and re-
nal replacement therapy at any time during the patient’s stay
in the ICU; status (alive/dead) at discharge from the ICU and
the date and time of discharge or death; status (alive/dead) at
discharge from hospital and the date of discharge or death.
Data for the CMPD are validated locally according to the
ICNARC CMP Dataset Specification and undergo extensive
validation for completeness, illogicalities, and inconsisten-
cies on pooling centrally. The validation process is repeated
until all queries have been resolved. The validated data are
then incorporated into the CMPD.
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Table 1. Description of the Intensive Care National Audit & Research Centre (ICNARC) risk prediction
model
Components of the model
Scores based on data collected during the first 24 hours in the ICU are used to produce an acute physiology
score and a predicted risk of hospital death
1. Physiology measured during the first 24 hours in the ICU
Highest heart rate Highest serum urea
Lowest systolic blood pressure Highest serum creatinine
Highest central temperature Highest serum sodium
Lowest respiratory rate Urine output (24 hr)
PaO2/FIO2 ratio / ventilation Lowest white blood cell count
Lowest arterial pH Glasgow Coma Scale score or sedated & paralysed
2. Source of admission
Elective surgery (direct from theater) Critical care transfer (admissions from an ICU or HDU
in the same or another hospital – direct or via accident
& emergency)
Emergency surgery (direct from theater) Accident & emergency (same hospital) or from any
location in another hospital (except ICU or HDU)
Ward (same hospital) Clinic or home
3. Cardiopulmonary resuscitation during the 24 hr prior to admission to the ICU (yes/no)
4. Diagnostic category
Respiratory Endocrine
Cardiovascular Hematological
Gastrointestinal Muscular-skeletal
Neurological Dermatological
Genitourinary
5. Age
HDU, high dependency unit; ICU, intensive care unit.
Primary and Secondary Outcome
Measures
The primary outcome measure was hospital mortality, de-
fined as death from any cause before ultimate discharge from
an acute hospital. The secondary outcomes were ICU mor-
tality, and length of stay in the ICU and in an acute hospital.
Sample Size
The sample size calculation was based on data from previous
NRSs (1;8;18) and on data kindly supplied by the Scottish
Intensive Care Society Audit Group (Fiona MacKirdy; per-
sonal communication) in 1999 from their database containing
details of all patients admitted to Scottish ICUs. These data
suggested a hospital mortality of around 50 percent for
patients managed with a PAC. It was calculated that a sample
of 1,076 patients (538 in each group) would have 90 percent
power to detect a 10 percent change in hospital mortality
based on a 5 percent level of significance for a two-sided
test.
Analyses
The analyses were conducted according to a predetermined
statistical analysis plan in Stata 10 (StataCorp, College Sta-
tion, Texas, USA).
Participating ICUs were compared with eligible non-
participating ICUs and to all general ICUs in the CMPD
according to hospital type (university, university-affiliated,
nonuniversity), size of unit (number of beds), activity (mean
number of admissions per year), and case-mix, as determined
by the ICNARC model predicted risk of hospital mortality
(Table 1) (14).
Re-admissions to the ICU during the same hospital stay
were identified. For patients admitted more than once during
the period, data from the first admission or from the first
admission during which the patient was managed with a PAC
were used. Patients with missing intervention or outcome
data were excluded from the analysis.
Univariate analyses were conducted to examine the in-
dependent variables for distribution of data and to identify
implausible values, outliers, etc. To assess whether any of the
independent variables were strongly related to one another,
Pearson’s correlation was used to examine variables in pairs.
Variables correlated at less than 0.8 were considered to be
acceptable for inclusion in the model.
The main analysis was a risk-adjusted comparison of pa-
tients managed with and without a PAC using the ICNARC
risk prediction model, which has been developed and vali-
dated for UK critical care and is based on the best elements
of existing models as well as further research into modeling
techniques (14). The propensity for being managed with a
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PAC was calculated by fitting a logistic regression model
with PAC as the outcome and the following independent
variables, which were identified by a review of previous stud-
ies (1;8;18) and consultation with 10 senior critical care doc-
tors: all variables collected for the ICNARC risk prediction
model (Table 1), sex, presence of chronic cardiovascular, res-
piratory, renal, liver or immune system disease, and arterial
base deficit/excess. Before constructing the logistic regres-
sion model, the association between the use of PAC and
the continuous independent variables, age and arterial base
deficit/excess, were examined for linearity. Restricted cubic
splines were used to allow for nonlinear relationships. Physi-
ological variables were entered into the model as categorical
variables based on scores (Table 1). Missing physiological
data were scored as normal (zero weighting).
Patients in the PAC group were then matched to patients
in the non-PAC group (1:2 without replacement) based on
their propensity score. A caliper size of a quarter of a standard
deviation of the logit of the propensity score was used (23).
First, a patient was randomly selected from the PAC group
and then all the patients in the non-PAC group were searched
for patients with the closest propensity score—to within 0.01
on a scale of 0 to 1. Where possible, two non-PAC patients
were matched to every PAC patient. The matched patients
were then removed from the pool and the process repeated.
Patients in either group who could not be matched to patients
in the other group were eliminated from the analysis. The
two groups were then compared to ensure that they were
similar with respect to baseline characteristics. In addition,
selected treatments given during the first 24 hours and at
any time during the ICU stay were also compared in the two
groups. Given the number of comparisons, tests of statistical
significance were not conducted.
The OR for death in hospital comparing patients man-
aged with a PAC to those managed without a PAC was derived
in a conditional logistic regression model using bootstrapped
standard errors. The Wald test was used to assess whether
the model accounted for hospital mortality better than would
be expected by chance.
The numbers of deaths before discharge from the ICU
were reported for PAC and non-PAC groups and the OR
calculated. Differences between the two groups in the dis-
tributions of lengths of stay in the ICU and in hospital were
compared using the Wilcoxon rank sum test.
RESULTS
ICU Characteristics
Of the 117 eligible ICUs invited, 68 agreed to participate. Of
these, eleven were excluded from the analysis for failing to
collect sufficient validated data on the use of PACs. Data from
fifty-seven ICUs were, therefore, included in the analysis. On
average, ICUs collected data for 18.8 months (standard de-
viation 4.24), ranging from 10 to 24 months. Participating
ICUs were more likely to be located in a university hospital
(30 percent versus 17 percent), to have 11 or more beds (25
percent versus 18 percent) and to have over 400 admissions
per year (54 percent versus 34 percent). The case-mix, as
determined by the ICNARC model predicted risk of hospi-
tal death for all admissions was, however, similar for both
participating and nonparticipating ICUs (Supplementary
Table 1, which is available at www.journals.cambridge.org/
thc2010006.
Patients and Data Quality
There were 42,939 patients admitted to the fifty-seven ICUs
of which, 40,880 (95 percent) met the inclusion criteria. Of
the 1,068 patients who were managed with a PAC, 19 were
lost to follow-up, leaving 1,049 available for the analysis. Of
the 38,597 patients managed without a PAC, 795 were lost to
follow-up, leaving 37,802 available for matching with PAC
group patients (Figure 1).
As the relationship between management with a PAC and
the continuous variables age and arterial base deficit/excess
was not linear, restricted cubic splines were used to model
these variables in the logistic regression model. A propen-
sity score was derived for 33,821 (87 percent) of the 38,851
patients available for analysis. Of the 1,049 PAC group pa-
tients, 1,024 (98 percent) were successfully matched to 2,048
non-PAC patients (Figure 1).
Comparison of Baseline Characteristics
and Treatment of Groups
The two groups were similar for all baseline characteris-
tics (Table 2) except a higher proportion of patients in
the PAC group had evidence of an infection on admission
to ICU (36 percent versus 29 percent), although the pro-
portion of patients whose infection was subsequently con-
firmed was similar for the two groups (9.2 percent versus 9.0
percent).
Some treatment differences were observed. A higher
proportion of patients in the PAC group received intravenous
vasoactive drug treatment during the first 24 hours (64 per-
cent versus 53 percent), were mechanically ventilated at some
stage (91 percent versus 84 percent), or had renal replace-
ment therapy during their stay in the ICU (44 percent versus
25 percent).
Outcomes
A higher proportion of patients in the PAC group (60 percent)
died in hospital than in the non-PAC group (54 percent)
(Table 3). The OR comparing patients managed with a PAC
with those managed without a PAC was 1.28 (95 percent CI,
1.06 – 1.55, bootstrapped standard error, 0.13). The effect of
management with a PAC on hospital mortality was examined
according to the predicted risk of hospital death. In the lower
risk groups, management with a PAC was associated with
increased odds of hospital death (Table 3).
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Eligible
n=40,880 
Excluded, n=1,215  
Use of PAC missing, n=163 
Data not clean, n=969 
Erroneous data, n=83 
Managed without a PAC 
n=38,597 
Managed with a PAC 
n=1,068 
Complete follow-up, 
n=37,802 (97.9%) 
Complete follow-up, 
n=1,049 (98.2%) 
Analyzed   
n=2,048 (6.2%) 
Analyzed 
n=1,024 (99.9%) 
Total  patients 
n=42,939 
n=39,665 
Loss to follow-up, 
n=795 (2.1%) 
Loss to follow-up, 
n=19 (1.8%) 
Propensity score derived 
n=32,796 (86.8%) 
Propensity score derived 
n=1,025 (97.7%) 
Missing data 
n=5006 (13.2%) 
Missing data 
n=24 (2.3%) 
Not matched 
n=30,748 (93.8%) 
Unable to match 
n=1 (<0.0%) 
Figure 1. Patient recruitment, based on the CONSORT Statement (2).
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Table 2. Comparison of Baseline Characteristics and Management of Patients by Treatment Group
Treatment group
Characteristic Non-PAC (n = 2,048) PAC (n = 1,024)
Propensity score, mean (SD) 0.08 (0.07) 0.08 (0.07)
Age, mean (SD) 62.3 (15.6) 61.9 (15.8)
Sex:, n (%):
Male 1,252 (61.1) 624 (60.9)
Female 796 (38.9) 400 (39.1)
Chronic disease present, n (%):
Cardiovascular 79 (3.9) 34 (3.3)
Respiratory 41 (2.0) 26 (2.5)
Liver 53 (2.6) 23 (2.3)
Renal 25 (1.2) 13 (1.3)
Immune 149 (7.3) 68 (6.6)
Likely infection on ICU admission, n (%):
No 679 (33.2) 290 (28.3)
Laboratory confirmed 185 (9.0) 94 (9.2)
Strongly suggestive from evidence 598 (29.2) 371 (36.2)
Arterial base deficit, median (IQR) −8.0 (−12.7 to −4.1) −8.1 (−12.6 to −4.2)
APACHE II (1st 24 hrs):
Acute physiology score, mean (SD) 17.2 (7.0) 17.7 (6.9)
Total score, mean (SD) 21.7 (7.5) 22.1 (7.4)
Predicted risk of death, median (IQR) 0.38 (0.21 – 0.57) 0.39 (0.23 – 0.59)
ICNARC model (1st 24 hours):
Acute physiology score, mean (SD) 28.2 (10.4) 27.9 (9.6)
Predicted risk of death, median (IQR) 0.61 (0.34 – 0.81) 0.60 (0.37 – 0.79)
Source of admission to the ICU, n (%):
Theatre and/or recovery 687 (33.3) 346 (33.8)
Ward same hospital 596 (29.1) 299 (29.2)
A&E same hospital 259 (12.7) 122 (11.9)
ICU/HDU same hospital 222 (10.8) 115 (11.2)
Other same hospital (including clinic/home) 125 (6.1) 64 (6.3)
Other hospital 159 (7.8) 78 (7.6)
Surgical status, n (%):
Non-surgical 1.382 (67.5) 695 (67.9)
Elective surgery 191 (9.3) 94 (9.2)
Emergency surgery 475 (23.2) 235 (23.0)
CPR within 24 hrs prior to admission to the ICU 142 (6.9) 74 (7.2)
During 1st 24 hours in the ICU, n (%):
Continuous intravenous vasoactive drug treatment for ≥hr 1,084 (52.9) 653 (63.8)
Mechanical ventilation 1,768 (86.3) 891 (87.0)
Never sedated/paralysed & sedated at any time 335 (16.4) 138 (13.5)
Sedated for whole of 1st 24 hrs 994 (48.5) 493 (48.1)
Paralysed & sedated for whole of 1st 24 hrs 88 (4.3) 37 (3.6)
Either sedated/paralysed & sedated for part of 1st 24 hrs 631 (30.8) 356 (34.8)
At any time during stay in the ICU, n (%):
Mechanical ventilation, n (%) 1,728 (84.4) 927 (90.5)
Renal replacement therapy, n (%) 503 (24.6) 454 (44.3)
PAC, pulmonary artery catheter; SD, standard deviation; IQR, interquartile range; A&E, Accident & Emergency; HDU, high dependency
unit; ICU, intensive care unit; ICNARC, Intensive Care National Audit & Research Centre; APACHE, Acute Physiology and Chronic
Health Evaluation.
A difference was also observed when ICU mortality was
considered: 53 percent in the PAC group versus 44 percent
in the non-PAC group; OR 1.50 (95 percent CI, 1.24 – 1.81,
bootstrapped standard error 0.15). Finally, hospital survivors
and nonsurvivors in the PAC group stayed longer in the ICU
and in hospital compared with those in the non-PAC group
(Table 3).
DISCUSSION
Main Findings
This study has demonstrated that it is feasible to carry out
a rigorous NRS of a healthcare intervention using an ex-
isting clinical database. We achieved high levels of agree-
ment from ICUs to participate (58 percent) of which most
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Table 3. Hospital Mortality Overall and by Predicted Risk, and Length of Stay in the
ICU and in Hospital by Treatment Group
Non-PAC PAC
Hospital mortality N (%) N (%) pa
Survivors 940 (45.9) 415 (40.5) .005
Non-survivors 1108 (54.1) 609 (59.5)
OR (PAC vs. no PAC) 1.28, 95% CI 1.06 – 1.55
Predicted riskb OR 95% CI SE
≤0.33 1.79 0.89 – 3.61 0.64
0.34 – 0.66 1.96 1.25 – 3.09 0.45
0.67 – 1.00 0.89 0.58 – 1.38 0.20
Length of stay (days) Median (IQR) Median (IQR) p c
ICU:
Survivors 5.0 (2.0 – 12.3) 10.3 (4.9 – 20.4) <.001
Non-survivors 1.7 (0.7 – 5.7) 3.2 (1.3 – 9.4) <.001
Hospital:
Survivors 28 (15 – 50.5) 38 (21 – 65) <.001
Non-survivors 8 (2 – 20) 9 (3 – 22) .001
ap value from Fisher’s exact test.
bIntensive Care National Audit & Research Centre (ICNARC) model predicted risk of death in hospital.
cp value from Wilcoxon rank sum test for difference in distribution.
PAC, pulmonary artery catheter; IQR, interquartile range; CI, confidence interval; SE, standard error
(bootstrapped); OR, odds ratio.
(84 percent) successfully collected the required additional
data. Although there was a slightly higher likelihood for
larger ICUs in university hospitals to participate, the case-
mix of patients was similar to that in nonparticipating ICUs.
Eligible patients were successfully identified and almost all
of those in the intervention group (98 percent) were suc-
cessfully matched on their propensity score to patients in
the control group. This created two groups with similar
baseline characteristics, allowing meaningful comparisons
of outcomes to be made. These suggested that the outcome
for PAC patients was significantly worse than for non-PAC
patients with regard to ICU mortality (OR 1.50; 95 per-
cent CI, 1.24 – 1.81) and hospital mortality (OR 1.28; 95
percent CI, 1.06 – 1.55). The large numbers of patients
available meant that subgroup analyses were possible and
these suggested poorer outcomes for those with predicted
risk of hospital death at admission to the ICU of less than
67 percent.
Strengths and Limitations
This study has three particular strengths compared with many
NRSs. First, it used data from a high-quality clinical database
that performs well against the quality criteria defined by
the Directory of Clinical Databases (10;13). The particu-
lar strengths of the CMPD are its wide coverage, making
it highly representative of the patient population, the use of
explicit definitions for all variables and rules for data collec-
tion, and employment of rigorous data validation methods.
Furthermore, collection of raw data enables risk adjustment
models to be derived using standard algorithms across all
ICUs to calculate scores and risks, allowing for better com-
parability of risk-adjusted outcomes (14). Second, unlike the
three previous NRSs that had been published at the time
(1;8;18), this study included a large number of ICUs, located
in both university and nonuniversity ICUs, ensuring high ex-
ternal validity. Third, the validity and predictive power of the
model used to adjust for case-mix was excellent (14). A major
strength of the model is that there are no exclusion criteria.
For many risk prediction models, these are often ill-defined,
poorly reported, and may exclude up to 15 percent of admis-
sions (25). Furthermore, inconsistent application of criteria
may introduce biases into risk-adjusted analyses (14). The
risk adjustment carried out in this study also included other
important prognostic factors: presence of chronic cardiovas-
cular, respiratory, renal, liver, or immune system disease; sex;
and arterial base deficit/excess.
The principal limitation, as with all NRSs, was uncer-
tainty as to whether all significant confounders had been
taken into account. All confounders identified by the lit-
erature review and through consultation with critical care
doctors were measured and included in the model with one
exception—the trajectory of a patient’s illness. Severity of ill-
ness, as determined by the ICNARC risk prediction model,
was measured using data collected during the first 24 hours
in the ICU. However, although two patients may have the
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same predicted risk of death at admission to the ICU, they
may be at different points in their illness trajectory. One may
have stabilized and be at their worst state of health, whereas
the other may be in decline leading toward a more severe
condition. Clinical deterioration or lack of response to treat-
ment was identified by critical care doctors, consulted before
the analysis, as one of the factors that influences their de-
cision to insert a PAC. Given that an arterial base deficit
(when there is increased acidity) is considered to be an
indicator of shock, injury, and inadequate resuscitation, they
suggested that the arterial base deficit/excess might indicate
how a patient was responding to treatment. This variable was
therefore included in the model as a covariate, and although
it may have been partly successful in adjusting for clinical
deterioration, a limitation was that only a single value of ar-
terial base deficit/excess was available, which was the worst
value measured during the first 24 hours in the ICU, and the
time of the measurement was not recorded. For some patients
their worst arterial base deficit might have occurred at admis-
sion to the ICU, but have improved later during the first 24
hours as they responded to treatment. For other patients, the
arterial base deficit might have worsened after admission to
the ICU as their clinical condition deteriorated. It was hard,
therefore, to make a distinction between these patients based
on a single measure.
Although matching on propensity score produced two
groups that were similar with respect to their baseline char-
acteristics, patients in the PAC group were more likely to have
received other additional interventions including vasoactive
drugs, mechanical ventilation, and renal replacement ther-
apy, indicating that they were a sicker group. It was not
appropriate, however, to include these interventions as co-
variates in the propensity score model as it was not known
when they were introduced relative to insertion of the PAC. It
does mean, though, that any difference in outcomes between
PAC and non-PAC groups should consider these concurrent
interventions when attributing causality.
Implications of the Findings
While this study has demonstrated the feasibility of conduct-
ing a rigorous NRS, the question remains as to the accuracy
of the findings given the inevitable uncertainty with regard
to its internal validity (threatened by unadjusted confound-
ing). A limitation of using secondary data is that detailed
information about the intervention of interest may not have
been recorded. In the case of this study, detailed information
relating to PAC use, such as the date and time of insertion and
the patient’s clinical condition at the time of insertion would
have been helpful and might have allowed for more accurate
adjustment for differences in baseline prognostic factors be-
tween the PAC and non-PAC groups. The matching strategy
was also limited because patients were matched on patient
characteristics during the first 24 hours in the ICU rather than
their characteristics up to and including the point at which
the PAC was inserted. Ideally, if the time of PAC insertion
had been known, PAC patients would have been matched to
controls who had spent at least as long in the ICU as the
PAC patients had before receiving a PAC. In other words,
matching would have included the time at risk of having a
PAC inserted. Investigators using data from clinical databases
should carefully consider therefore the additional data that
may be needed to enable a rigorous case-mix adjusted evalu-
ation of the intervention of interest. However, this does have
to be weighed against the available resources and practicality
of collecting additional data.
The findings of this study are consistent with the range
of ORs reported by the three previous NRSs (1.08 to 1.54),
which had all suggested that management with a PAC is as-
sociated with higher hospital mortality compared with man-
agement without a PAC in general ICU populations (1;8;18).
In addition, two of these studies also reported that poorer out-
come was restricted to patients at lower baseline risk (8;18).
Since 2002, three further NRSs have been published, two
based on data from single North American university hospi-
tals (7;20) and one on 198 European hospitals (24). While
one study (20) reported a significantly higher risk of death
with PAC use (OR 1.5; 95 percent CI, 1.1 – 2.0), the other
two found statistically insignificant differences (ORs 1.05;
95 percent CI, 0.92 – 1.21 and 1.04, 95 percent C 0.79 –
1.38, respectively) (7;24). The only study to report subgroup
analyses found that the risk associated with PAC use was
confined to less sick patients (7), consistent with this and
earlier studies.
An important question, given the limitations relating to
their internal validity, is whether NRSs can provide reli-
able estimates of treatment effect. One approach to inves-
tigating the accuracy of a NRS is to compare its results
with one or more RCTs (15). This is currently under way
and will be reported elsewhere. Meanwhile, this study has
demonstrated the feasibility and methodological rigor that
can be brought to bear in NRSs. Given the relatively low
cost of a study design that is nested in an existing database
(thereby incurring little cost for data collection and process-
ing as most of the data have already been collected for clin-
ical audit) compared with a RCT, plus the many occasions
when a randomized design is not possible (4), this study
serves to demonstrate the great potential NRSs could offer.
This will only be realized if high-quality clinical databases,
such as the one used in this study, are established and
supported. The need for ongoing development in the identifi-
cation and measurement of confounding factors (as demon-
strated in this study by the need to try and incorporate a
measure of the patient’s illness trajectory) must continue to
be addressed.
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